Home
Live Updates
AIM ImmunoTech Inc.: AIM ImmunoTech Provides Summary of Ampligen Data Supporting Synergistic Potential with Checkpoint Blockade Therapies : comparemela.com
AIM ImmunoTech Inc.: AIM ImmunoTech Provides Summary of Ampligen Data Supporting Synergistic Potential with Checkpoint Blockade Therapies
Ampligen has demonstrated in pre-clinical and now human clinical studies a potential to enhance efficacy of PD-1 and/or PD-L1 checkpoint inhibitors Ampligen's anti-tumor potential is demonstrated with
Related Keywords
United States ,
American ,
Pawel Kalinski ,
Jenene Thomas ,
Michael Tony Hollingsworth ,
Roswell Park ,
Robert Edwards ,
Bob Edwards ,
Cancersshowing Ampligen ,
Thomas Equels ,
Roswell Park Comprehensive Cancer Center ,
Immunotech Inc ,
University Of Nebraska Medical Center ,
University Of Pittsburgh Medical Center ,
University Of Pittsburgh School Medicine ,
University Of Pittsburgh Cancer Institute ,
Buffett Cancer Center ,
Division Of Translational Immuno ,
Steam Science ,
Chief Executive Officer ,
Associate Director ,
Basic Research ,
Nebraska Medical ,
Pittsburgh School ,
Pittsburgh Cancer ,
Jacobs Family Endowed Chair ,
Translational Immuno Oncology ,
Senior Vice President ,
Roswell Park Comprehensive Cancer ,
Ovarian Cancer ,
Pittsburgh Medical Center ,
Triple Negative Breast Cancer ,
Private Securities Litigation Reform Act ,
Immunotech ,
Rovides ,
Summary ,
Ampligen ,
Data ,
Supporting ,
Synergistic ,
Potential ,
Checkpoint ,
Blockade ,
Therapies ,
comparemela.com © 2020. All Rights Reserved.